LYMPHOMA, T-CELL, PERIPHERAL
Clinical trials for LYMPHOMA, T-CELL, PERIPHERAL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL, PERIPHERAL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, PERIPHERAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New lymphoma drug enters first human safety tests
Disease control TerminatedThis study tested a new experimental drug called PF-08046044/SGN-35C in 58 adults with advanced lymphomas (Hodgkin, T-cell, or B-cell types) that had not responded to other treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated e…
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 26, 2026 10:09 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046045, in people with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, and only 22 people took part.
Matched conditions: LYMPHOMA, T-CELL, PERIPHERAL
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 26, 2026 10:06 UTC